RxDoctor Payments Data

Gladys Ogbonna, MD

Internal Medicine · Longview, TXNPI 1023542818

Payments from drug & device makers

$1,507in general payments, 2019–2025

Across 87 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$422
  • Lilly USA, LLC$415
  • Astellas Pharma US Inc$150
  • Amgen$107
  • AbbVie$64
  • Biohaven Pharmaceuticals, Inc.$54
  • plus $296 from 12 others

What the payments were for

  • Food & beverage$1,507100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,507 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$92,677
Medicare patients
223
Services billed
1,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$68,525
EliquisApixaban56$58,857
MounjaroTirzepatide30$37,760
XareltoRivaroxaban22$25,624
ProliaDenosumab14$23,692
MyrbetriqMirabegron18$21,680
JardianceEmpagliflozin14$21,648
FarxigaDapagliflozin Propanediol17$14,320
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$11,435
Spiriva RespimatTiotropium Bromide11$10,661
Janumet XrSitagliptin Phos/Metformin Hcl11$10,450
ByettaExenatide11$9,371
Atorvastatin Calcium490$4,214
Levothyroxine Sodium345$3,952
Rosuvastatin Calcium165$3,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$422$68,52552 claims
PfizerEliquis$51$58,85756 claims
Lilly USA, LLCMounjaro$415$37,76030 claims
Boehringer IngelheimJardiance, Spiriva Respimat$17$32,30925 claims
AmgenProlia$107$23,69214 claims
Astellas Pharma US IncMyrbetriq$150$21,68018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →